ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly consolidated sales rebates and discounts liability ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets
Latest, Q2 2026
21,122
Period ended Jun 30, 2026
Change on a year earlier
+45.3%
14,537 in Q2 2025
History
36 quarters
Since Q4 2016
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated sales rebates and discounts liability ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 21,122 | +45.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 17,547 | +51.9% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 17,382 | +50.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 17,620 | +41.8% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 14,537 | +16.8% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 11,550 | +22.5% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 11,539 | -1.3% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 12,430 | +7.9% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 12,447 | +19.8% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 9,430 | -1.0% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 11,689 | +33.1% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 11,522 | +34.5% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 10,390 | +30.0% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 9,530 | +40.8% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 8,784 | +28.3% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 8,568 | +19.2% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | 7,991 | +13.6% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 6,769 | +16.3% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 6,846 | +17.0% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 7,186 | +25.1% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2021 | Jun 30, 2021 | 7,036 | +33.2% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 5,821 | +23.8% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 5,853 | +18.6% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 5,745 | +8.9% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 5,282 | +5.8% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 4,704 | +5.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 4,934 | +1.7% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2019 | Sep 30, 2019 | 5,277 | +2.9% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 4,994 | +5.2% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 4,456 | +2.5% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 4,850 | +8.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 5,129 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 4,745 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2018 | Mar 31, 2018 | 4,348 | – | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 4,465 | +14.1% | Form 10-K (filed 2019-02-19) ↗ |
| Q4 2016 | Dec 31, 2016 | 3,915 | – | Form 10-K (filed 2018-02-20) ↗ |
Breakdown
What makes up consolidated sales rebates and discounts liability ($m)
Cite this data
StockData. (2026). Eli Lilly Consolidated sales rebates and discounts liability ($M) ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/gtn_rebates_liab_cons
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.